1. Home
  2. ELDN vs XRPN Comparison

ELDN vs XRPN Comparison

Compare ELDN & XRPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eledon Pharmaceuticals Inc.

ELDN

Eledon Pharmaceuticals Inc.

HOLD

Current Price

$3.54

Market Cap

291.8M

Sector

Health Care

ML Signal

HOLD

Logo Armada Acquisition Corp. II Class A Ordinary Shares

XRPN

Armada Acquisition Corp. II Class A Ordinary Shares

HOLD

Current Price

$10.49

Market Cap

328.9M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
ELDN
XRPN
Founded
2004
2024
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Blank Checks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
291.8M
328.9M
IPO Year
2014
2025

Fundamental Metrics

Financial Performance
Metric
ELDN
XRPN
Price
$3.54
$10.49
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$8.50
N/A
AVG Volume (30 Days)
910.2K
44.0K
Earning Date
05-12-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
30.67
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$72.74
Revenue Growth
N/A
N/A
52 Week Low
$1.35
$10.10
52 Week High
$4.60
$10.50

Technical Indicators

Market Signals
Indicator
ELDN
XRPN
Relative Strength Index (RSI) 45.41 64.05
Support Level $3.31 $10.43
Resistance Level $4.17 N/A
Average True Range (ATR) 0.18 0.02
MACD 0.02 0.00
Stochastic Oscillator 46.40 97.86

Price Performance

Historical Comparison
ELDN
XRPN

About ELDN Eledon Pharmaceuticals Inc.

Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.

About XRPN Armada Acquisition Corp. II Class A Ordinary Shares

Armada Acquisition Corp II is a blank check company.

Share on Social Networks: